Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis

Esta versión no es la más reciente

ver la versión actual 18 diciembre 2018

Información

DOI:
https://doi.org/10.1002/14651858.CD012577Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 11 abril 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud ocular y de la visión

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Mohammad O Tallouzi

    Correspondencia a: Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

    [email protected]

    [email protected]

  • Robert J Barry

    Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Nick Bucknall

    Shrewsbury, UK

  • Jonathan M Mathers

    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Philip I Murray

    Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Melanie J Calvert

    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • David J Moore

    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Alastair K Denniston

    Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Contributions of authors

MT drafted the manuscript. MT, AD, DM, RB and MC led the development of the protocol. AD, RB and PM provided clinical advice; DM and MC provided methodological advice. NB provided the patient public perspective. JM has given input in reviewing protocol. All authors read and approved the final manuscript.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • National Institute for Health Research, UK.

    • Richard Wormald, Co‐ordinating Editor for the Cochrane Eyes and Vision Group (CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.

    • The NIHR also funds the CEVG Editorial Base in London.

    The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of Health.

Declarations of interest

MT: none known.
RB: none known.
PM: none known.
MC: none known.
DM: none known.
AD: none known.

Acknowledgements

We thank Anupa Shah, Managing Editor for Cochrane Eyes and Vision (CEV) for help during the preparation of this protocol. This protocol represents an independent research project funded by the National Institute for Health Research (NIHR) under the Clinical Doctoral Research Fellowship Scheme being undertaken at the University of Birmingham. The views expressed in this protocol are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2018 Dec 18

Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis

Review

Robert J Barry, Mohammad O Tallouzi, Nick Bucknall, Jonathan M Mathers, Philip I Murray, Melanie J Calvert, David J Moore, Alastair K Denniston

https://doi.org/10.1002/14651858.CD012577.pub2

2017 Apr 11

Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis

Protocol

Mohammad O Tallouzi, Robert J Barry, Nick Bucknall, Jonathan M Mathers, Philip I Murray, Melanie J Calvert, David J Moore, Alastair K Denniston

https://doi.org/10.1002/14651858.CD012577

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.